Amersham targets Alzheimer's disease
British pharmaceutical and life sciences company Amersham has obtained an exclusive license from the University of Pittsburgh to a class of molecules that target amyloid plaque in the brain, the cause of Alzheimer's disease. Amersham will attempt to
British pharmaceutical and life sciences company Amersham has obtained an exclusive license from the University of Pittsburgh to a class of molecules that target amyloid plaque in the brain, the cause of Alzheimer's disease. Amersham will attempt to develop PET agents for diagnosing and monitoring the progress of the disease. Such agents could accelerate the development of a wide range of therapeutics for Alzheimer's by allowing doctors to definitively measure the effectiveness of a potential therapy, according to the company.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
